IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#836
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$471M
Robert G. Kramer
Emergent BioSolutions focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = EBS ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EBS Emergent BioSolutions Inc. | 59 | 72 | 94 | 57 | 2.6x | 6.6x | 38.1% | 15.2% | 57.6% | 19.7% | 20.8% | -9.3% | 0.0% | 119.0x | $471M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Emergent BioSolutions Inc. (EBS) receives a "Hold" rating with a composite score of 58.5/100. It ranks #836 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Headcount
2.4K
HQ Base
Gaithersburg, Maryland
In-line with peers — no strong momentum signal
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for EBS.
View All RatingsROIC 15.3% vs WACC 5.5% (spread +9.8%)
GM 58% vs sector 44%, OM 20% vs sector 3%
Capital turnover 0.52x, R&D intensity 6.9%
Rev growth -9%, 10yr history
Interest coverage 5.0x, Net debt/EBITDA 5.9x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Emergent BioSolutions Inc. (EBS) as a Hold with a composite score of 58.5/100 at a current price of $10.96. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Emergent BioSolutions Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 58.5/100 places it at rank #836 in our full universe.
No Moat
High
Standard
Undervalued
Gross margins of 58% signal strong pricing power.
Returns on equity of 38.1% exceed cost of capital.
Value factor score of 94 suggests attractive pricing.
Leverage of 119% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
Emergent BioSolutions Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns Emergent BioSolutions Inc. a Hold rating, with a composite score of 58.5/100 and 3 out of 5 stars. Ranked #836 of 7,333 stocks, EBS presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
EBS earns a quality score of 72/100, indicating above-average business quality. The company reports a return on equity of 38.1% (sector avg: -1.9%), gross margins of 57.6% (sector avg: 44.1%), net margins of 20.8% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
From a valuation perspective, EBS scores an exceptional 94/100, indicating the stock trades at a deep discount relative to its fundamentals. Key valuation metrics include a P/E ratio of 2.59x, an EV/EBITDA of 6.58x, a P/B ratio of 0.99x. A value score this high suggests the market may be significantly underpricing the company's earnings power, assets, or cash flow generation.
With an investment score of 52/100, EBS exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of -9.3% vs. a sector average of 6.7% and a return on assets of 15.2% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
EBS demonstrates moderate momentum with a score of 57/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -9.3% year-over-year, while a beta of 1.54 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
EBS's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.54 and a debt-to-equity ratio of 119.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Emergent BioSolutions Inc.'s short interest score of 30/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.54), elevated leverage (D/E: 119.00x), small-cap liquidity risk. At $471M (small-cap), EBS carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Emergent BioSolutions Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #836 of 7,333 overall (89th percentile). Key comparisons include ROE of 38.1% exceeding the -1.9% sector median and operating margins of 19.7% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While EBS currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (94) vs Short Int. (30) — closing this gap could shift the rating.
EV/EBITDA 43% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 2106% BELOW SECTOR MEDIAN
Gross Margin 31% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
Emergent BioSolutions has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The deal enables Emergent to streamline operations while maintaining flexibility for future product demand.
A former biotech CEO pocketed more than $10 million by selling company stock after learning of serious COVID-19 vaccine contamination problems — before those issues were made public, according to a lawsuit.The alleged trades are detailed in a lawsuit filed Thursday, Jan. 15, by New York Attorney Ge…
Emergent BioSolutions stock surged nearly 12% after an analyst at H.C. Wainwright initiated coverage with a buy recommendation and a $15 price target, citing the company's diversified offerings and growth potential in its Narcan opioid reversal spray and vaccines business.
Emergent BioSolutions' shares fell nearly 6% after the company disclosed that several institutional shareholders are selling their shares and warrants. The selling is not dilutive for Emergent, but investors are wary of the potential impact on the company's future.